EUCTR2010-018319-13-BG进行中（未招募）不适用
A DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP STUDY ASSESSING THE ACTIVITY OF CD5024 1% CREAM IN SUBJECTS WITH PAPULOPUSTULAR ROSACEA OVER 12 WEEKS TREATMENT
GALDERMA R&D SNC0 个研究点目标入组 317 人开始时间: 2011年2月24日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 317
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. The subject is a male or female 18 years of age or older.
- •2. The subject has papulopustular rosacea, with an Investigator Global Assessment (IGA), score rated = 3.
- •3. The subject has at least 15 inflammatory lesions (papules and pustules) on the face.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. The subject has particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin) or other dermatoses that may be confounded with papulopustular rosacea, such as peri oral dermatitis, demodicidosis, facial keratosis pilaris, seborrheic dermatitis.
- •2. The subject has ocular rosacea requiring either a systemic treatment or an interfering treatment.
- •3. The subject has an underlying known disease, a surgical or medical condition, which in the judgment of the investigator, would put the subject at risk, or might confound the study assessments, or might interfere with the subject’s participation in the study
研究者
相似试验
进行中（未招募）
不适用
A DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP STUDY ASSESSING THE ACTIVITY OF CD5024 1% CREAM IN SUBJECTS WITH PAPULOPUSTULAR ROSACEA OVER 12 WEEKS TREATMENTPATIENTS WITH PAPULOPUSTULAR ROSACEAMedDRA version: 9.1Level: LLTClassification code 10039218Term: RosaceaEUCTR2010-018319-13-DEGALDERMA R&D SNC317
进行中（未招募）
不适用
A DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP STUDY ASSESSING THE ACTIVITY OF CD5024 1% CREAM IN SUBJECTS WITH PAPULOPUSTULAR ROSACEA OVER 12 WEEKS TREATMENTPATIENTS WITH PAPULOPUSTULAR ROSACEAMedDRA version: 9.1Level: LLTClassification code 10039218Term: RosaceaEUCTR2010-018319-13-HUGALDERMA R&D SNC317
进行中（未招募）
不适用
A DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP STUDY ASSESSING THE ACTIVITY OF CD5024 1% CREAM IN SUBJECTS WITH PAPULOPUSTULAR ROSACEA OVER 12 WEEKS TREATMENTPATIENTS WITH PAPULOPUSTULAR ROSACEAMedDRA version: 9.1Level: LLTClassification code 10039218Term: RosaceaEUCTR2010-018319-13-FIGALDERMA R&D SNC317
进行中（未招募）
1 期
A DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP STUDY ASSESSING THE ACTIVITY OF CD5024 1% CREAM IN SUBJECTS WITH PAPULOPUSTULAR ROSACEA OVER 12 WEEKS TREATMENTEUCTR2010-018319-13-CZGALDERMA R&D SNC317
进行中（未招募）
1 期
A DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP STUDY ASSESSING THE ACTIVITY OF CD5024 1% CREAM IN SUBJECTS WITH PAPULOPUSTULAR ROSACEA OVER 12 WEEKS TREATMENTPATIENTS WITH PAPULOPUSTULAR ROSACEAMedDRA version: 9.1Level: LLTClassification code 10039218Term: RosaceaEUCTR2010-018319-13-SKGALDERMA R&D SNC317